A Randomized, Placebo-Controlled Trial of Three Fixed Dosages of Prolonged-Release OROS Methylphenidate in Adults with Attention-Deficit/Hyperactivity Disorder

Biological Psychiatry

Volumn 63, Issue 10, 2008, Pages 981-989

  Medori, Rossella ^a   Ramos Quiroga, J Antoni ^b,c   Casas, Miguel ^b,c   Kooij, J J S ^d   Niemelä, Asko ^e   Trott, Götz Erik ^f   Lee, Emma ^g   Buitelaar, Jan K ^a,h  

^a JANSSEN CILAG GMBH   (Germany)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d Program Adult ADHD   (Netherlands)

^e OULU UNIVERSITY HOSPITAL   (Finland)

^f Janssen Belgium ^*

^g JANSSEN RESEARCH FOUNDATION   (Belgium)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ADHD; adult; methylphenidate; prolonged release; randomized trial; stimulant

Indexed keywords

METHYLPHENIDATE; PLACEBO;

ADULT; AGED; AGGRESSION; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONNERS ADULT ADHD RATING SCALE; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DECREASED APPETITE; DELUSION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; INCIDENCE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL IRRITATION; NERVOUSNESS; PRIORITY JOURNAL; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESTLESSNESS; SIDE EFFECT; TACHYCARDIA; TINNITUS; TREATMENT OUTCOME; TREMOR; WEIGHT REDUCTION; XEROSTOMIA;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSION PUMPS, IMPLANTABLE; MALE; METHYLPHENIDATE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 42649133116     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2007.11.008     Document Type: Article

References (33)

1. Faraone S.V., Biederman J., and Mick E. The age-dependent decline of attention deficit hyperactivity disorder: A meta-analysis of follow-up studies. Psychol Med 35 (2005) 1-7
2. Kessler R.C., Adler L., Barkley R., Biederman J., Conners C.K., Demler O., et al. The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey Replication. Am J Psychiatry 163 (2006) 716-723
3. Kessler R.C., Adler L.A., Barkley R., Biederman J., Conners C.K., Faraone S.V., et al. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: Results from the national comorbidity survey replication. Biol Psychiatry 57 (2005) 1442-1451
4. Fayyad J., De Graaf R., Kessler R., Alonso J., Angermeyer M., Demyttenaere K., et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 190 (2007) 402-409
5. Greenhill L.L., Pliszka S., Dulcan M.K., Bernet W., Arnold V., Beitchman J., et al. Summary of the practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 40 (2001) 1352-1355
6. U.S. Food and Drug Administration. FDA Directs ADHD Drug Manufacturers to Notify Patients about Cardiovascular Adverse Events and Psychiatric Adverse Events (2007), National Press Office, Rockville, MD Press P07-26
7. Anders T., and Sharfstein S. ADHD drugs and cardiovascular risk. N Engl J Med 354 (2006) 2296-2298 author reply 2296-2298
8. Nissen S.E. ADHD drugs and cardiovascular risk. N Engl J Med 354 (2006) 1445-1448
9. Okie S. ADHD in adults. N Engl J Med 354 (2006) 2637-2641
10. Rappley M.D., Moore J.W., and Dokken D. ADHD drugs and cardiovascular risk. N Engl J Med 354 (2006) 2296-2298 author reply 2296-2298
11. Wojnowski L. ADHD drugs and cardiovascular risk. N Engl J Med 354 (2006) 2296-2298 author reply 2296-2298
12. Asherson P., Chen W., Craddock B., and Taylor E. Adult attention-deficit hyperactivity disorder: Recognition and treatment in general adult psychiatry. Br J Psychiatry 190 (2007) 4-5
13. Asherson P. Clinical assessment and treatment of attention deficit hyperactivity disorder in adults. Expert Rev Neurother 5 (2005) 525-539
14. Wolraich M.L., Greenhill L.L., Pelham W., Swanson J., Wilens T., Palumbo D., et al. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 108 (2001) 883-892
15. Swanson J., Gupta S., Lam A., Shoulson I., Lerner M., Modi N., et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: Proof-of-concept and proof-of-product studies. Arch Gen Psychiatry 60 (2003) 204-211
16. Pelham W.E., Gnagy E.M., Burrows-Maclean L., Williams A., Fabiano G.A., Morrisey S.M., et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 107 (2001) E105
17. Bouffard R., Hechtman L., Minde K., and Iaboni-Kassab F. The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Can J Psychiatry 48 (2003) 546-554
18. Faraone S.V., Spencer T., Aleardi M., Pagano C., and Biederman J. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 24 (2004) 24-29
19. Spencer T., Biederman J., Wilens T., Doyle R., Surman C., Prince J., et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 57 (2005) 456-463
20. Kooij J.J., Burger H., Boonstra A.M., Van der Linden P.D., Kalma L.E., and Buitelaar J.K. Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychol Med 34 (2004) 973-982
21. Biederman J., Mick E., Surman C., Doyle R., Hammerness P., Harpold T., et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 59 (2006) 829-835
22. Reimherr F.W., Williams E.D., Strong R.E., Mestas R., Soni P., and Marchant B.K. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry 68 (2007) 93-101
23. Jain U., Hechtman L., Weiss M., Ahmed T.S., Reiz J.L., Donnelly G.A., et al. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: Results of a double-blind, placebo-controlled crossover study. J Clin Psychiatry 68 (2007) 268-277
24. Spencer T.J., Adler L.A., McGough J.J., Muniz R., Jiang H., and Pestreich L. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 61 (2007) 1380-1387
25. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text Revision (2000), The American Psychiatric Association, Washington, DC
26. Conners C., Erhardt D., and Sparrow E. Conners' Adult ADHD Rating Scales (CAARS): Technical Manual (1999), Multi-Health Systems, North Tonawanda, NY
27. First M., Spitzer R., Gibbon M., and Williams G. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P), Version 2 (1994), New York State Psychiatric Institute, Biometrics Research, New York
28. Michelson D., Adler L., Spencer T., Reimherr F.W., West S.A., Allen A.J., et al. Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies. Biol Psychiatry 53 (2003) 112-120
29. National Institute of Mental Health (NIMH). CGI (Clinical Global Impression Scale)-NIMH. Psychopharmacol Bull 21 (1985) 839-843
30. Spencer T., and Adler L. Diagnostic approaches to adult attention-deficit/hyperactivity disorder. Prim Psychiatry 11 (2004) 49-56
31. Nutt D.J., Fone K., Asherson P., Bramble D., Hill P., Matthews K., et al. Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol 21 (2007) 10-41
32. Kooij J.J., Buitelaar J.K., van den Oord E.J., Furer J.W., Rijnders C.A., and Hodiamont P.P. Internal and external validity of attention-deficit hyperactivity disorder in a population-based sample of adults. Psychol Med 35 (2005) 817-827
33. Banaschewski T., Coghill D., Santosh P., Zuddas A., Asherson P., Buitelaar J., et al. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 15 (2006) 476-495